Lilly Retatrutide Lawsuits: Who Was Sued and What Changed

By The RX Index Editorial Team · Last verified October 2026

Lilly's retatrutide lawsuits in two 2026 filing rounds target sellers, not patients. Eli Lilly filed six cases on August 12 and five on October 8 against businesses or operators it says sold unapproved retatrutide. One case is dismissed. We found no judgment deciding the claims against these sellers in the public records reviewed.

What can change this: new lawsuits, settlements and court rulings. We checked the available records linked below on October 14, 2026. This is a tracker of those two filing rounds, not every Lilly lawsuit or 11 still-open cases.

And here's the other case to watch. Lilly isn't just suing sellers. It's also fighting the FDA over which rules retatrutide should follow. That dispute could shape future competition, but it isn't a decision to approve the drug.

Jump to: The 11 tracked cases · What it means if you bought "reta" · Lilly vs. the FDA

Lilly retatrutide lawsuits, case by case

This tracker covers 11 federal lawsuits against sellers of products marketed as retatrutide: six filed on August 12, 2026, and five on October 8, 2026. They were filed in courts in California, Texas, Louisiana and Arizona. Each of these cases names a business or business operator as the defendant (the person or company being sued), not a customer.

Each row links to the public court record. A complaint is the document where the person suing lays out what they say happened and what they want the court to do. Filing one starts a case. It doesn't prove the allegations.

The six cases filed August 12, 2026

The five cases filed October 8, 2026

Two things to know before you use this list:

• One correction to the record. Lilly's August 12 announcement lists the Aesthetic Envy case in the Northern District of California. The court filings show the Eastern District. We go with the court record.
• Not on this list doesn't mean safe. These tables cover the two filing rounds named above. A seller missing from this list hasn't been checked or cleared. FDA approval does not follow from staying out of a lawsuit.

Lilly says the lawsuits are only part of its push. As of August 12, it said it had referred more than 200 people and businesses to the FDA, the Justice Department, state attorneys general and licensing boards. It also said it had reported more than 14,000 websites, ads, posts and listings in over 100 countries (Lilly announcement, Aug 12, 2026).

Has Lilly won any of these cases?

We found no judgment deciding the claims against these 11 sellers in the public records checked October 14, 2026. Lilly dismissed one whole case, news reporting describes two settlements, and Legendary is asking a judge to throw its case out. Those developments are not a court finding that a product was safe.

Here's each development in plain words:

• Aesthetic Envy (dismissed). On September 11, Lilly filed a notice dropping "the above-captioned action, in its entirety" "with prejudice" (notice). "With prejudice" means Lilly cannot refile those same dismissed claims against that defendant. The notice doesn't say why, and it mentions no settlement or payment.
• Texas Peptides (settled, Lilly says). Becker's reports that a Lilly spokesperson told The Washington Post that two August cases settled. According to that report, Texas Peptides agreed to stop selling, tell customers to stop using the products, and donate to America's Poison Centers (report). That report does not identify the second case. We did not obtain a settlement agreement, and the public docket copy we checked did not show the settlement.
• Legendary Peptides (asking for dismissal). Legendary asked the court to dismiss the case on October 2. Its main point: Lilly can't claim it was hurt by sales of "a product it does not and cannot lawfully sell." It also argues Lilly hasn't shown any real loss caused by Legendary (motion). That's Legendary's argument, not a ruling.
• Astra (unclear). Lilly filed a notice of voluntary dismissal on September 2, but later entries show more activity. On September 30, it asked to take discovery "to determine Defendant's identity" before serving the lawsuit. Discovery is the formal process of seeking documents or testimony, sometimes from third parties. We could not retrieve the dismissal notice, so we can't say what was dropped.

"Sued," "asked to dismiss" and "dismissed" mean different things

Say you saw a "case dismissed" headline in September, then a "Lilly sues five more" headline in October. Those can be about totally different businesses. Match the seller name and case number first. One case's result doesn't decide any other.

Why is Lilly suing sellers of a drug it doesn't sell yet?

Lilly says these businesses sold unapproved retatrutide to consumers for weight loss, misled buyers about what they were getting, and are pulling patients away from its approved medicines. The legal claims are mostly false advertising and unfair competition. The complaints discussed below seek relief for alleged business harm, not patent infringement or patient injuries.

The details differ by case. Two complaints we read show the pattern:

• Medrein Health & Aesthetics (a Texas med spa). Lilly says it called its retatrutide product an "advanced therapy" for people who had plateaued on other GLP-1s, compared it to Mounjaro and Zepbound, and said it came from "reputable compounding pharmacies." Lilly sued under the Lanham Act, the federal false-advertising law. It asks for a court order to stop the ads, plus corrective ads (complaint).
• LiveWell Peptides (one person selling under a business name). Lilly says the "research use only" label was a cover for selling to people. As evidence, it points to reconstitution and dosing information the seller shared with buyers. Lilly sued under unfair-competition laws in seven states plus Texas common law (complaint).

What Lilly is asking for: in the two complaints discussed here, permanent orders restricting the sale or advertising of products that contain, or claim to contain, retatrutide. The exact requests differ. Lilly also seeks profits, damages and legal fees. Think of it as asking the court to stop the challenged business practices and award money to Lilly—not a refund program for buyers. Asking isn't the same as getting it.

Why Lilly says it's harmed: customers switching from its approved drugs to cheaper gray-market vials, and bad reactions that could make people distrust the real medicine if it's approved.

What the sellers say: one response we reviewed is Legendary's motion. It argues that Lilly has not shown a legally recognized injury caused by Legendary's conduct. We found no ruling deciding that motion in the records reviewed.

What this means if you bought or used "reta"

None of these 11 cases names a customer as a defendant. That does not settle anyone's individual legal position. No web page, including this one, can verify what was in your vial.

Your own clinician can help you decide what to do next. Find your situation:

Safety note: If you have severe stomach pain, a racing heartbeat, fainting, trouble breathing, or signs of serious dehydration after using a product sold as retatrutide, get medical care now. Call 911 in an emergency. Poison Control is free at 1-800-222-1222, any time (America's Poison Centers).

For adults who feel well and are weighing treatment options: if you were using reta because you wanted strong results at a price you could manage, ask about approved options. But the right one isn't the same for everyone. It depends on your state, your insurance and the drugs your plan covers, whether an FDA-approved medicine meets your medical needs, a shot or a pill, and your budget. Compounding is a separate, non-FDA-approved path with legal limits—not a workaround for retatrutide. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows GLP-1 paths and providers based on your answers. It's free, takes about 2 minutes, and needs no signup. It doesn't offer retatrutide.

See which legal GLP-1 path fits you

Does "research use only" make retatrutide legal?

Not for sales intended for human use. The FDA says retatrutide "cannot be used in compounding under federal law." It has warned companies selling it labeled "for research purposes" or "not for human consumption" while selling it to people with dosing instructions. The FDA urges consumers not to buy these products, calling them "of unknown quality" (FDA, checked Oct 14, 2026).

Three labels sellers lean on, and what they really mean:

• "Research use only." A lab label does not turn a product marketed for human use into an approved medicine. Lilly argues that these labels did not match how the products were sold. Genuine laboratory research is a different question.
• "Compounded retatrutide." Compounding involves combining or changing ingredients to prepare a medicine for a medical need. It can occur in a pharmacy or another legally permitted setting. Compounded drugs aren't FDA-approved, and the FDA doesn't review them for safety, effectiveness or quality before they're sold (FDA). For retatrutide specifically, the FDA says compounding isn't allowed at all. A prescription doesn't change that.
• "Third-party tested" or a lab report. A lab report describes findings for the sample tested. It isn't FDA approval or, by itself, proof of what's in your vial or that it stayed sterile. We did not authenticate any seller's report.

Lilly's August 12 statement said retatrutide had not been approved by any regulator anywhere in the world. See Lilly's statement. For the bigger picture on compounding rules, see compounded vs. name-brand GLP-1s.

Has anyone been hurt by black-market retatrutide?

Outside the U.S., Victoria's health department in Australia reported six cases of acute liver injury since January 2026 in people who used unapproved products labelled retatrutide. Officials said contaminants might be involved (Victoria Department of Health, June 19, 2026).

CBS News reported two death reports submitted to FDA after people used products sold as retatrutide: one in July 2026 and one in September 2026. We could not retrieve the underlying report copies. The news report does not establish that the products caused either death (CBS News, Oct 13, 2026).

CBS also reported Lilly's statement that neither person was in a clinical trial and that the company had found suspect products with too much, too little or the wrong active ingredient, plus contaminants. Those are reported company statements, not our testing.

CBS reported these counts of retatrutide exposures from America's Poison Centers. We checked the figures against that news report, but did not obtain the underlying data extract:

An "exposure" means reported contact with a substance, not necessarily poisoning or injury. These counts do not measure how many people use retatrutide or their risk of harm. America's Poison Centers says reports can be incomplete and counts can change with publicity, reporting and substance coding (data limitations).

For what side effects looked like in Lilly's own trials, see retatrutide side effects. Keep in mind that an unknown vial may not match the trial drug at all.

Lilly's other retatrutide lawsuit: its fight with the FDA

Since 2024, Lilly has been suing the FDA to have retatrutide treated as a "biological product" instead of a regular drug. On October 2, 2026, the FDA again concluded that retatrutide is "neither a protein nor an analogous product to a protein" and so is not a biological product (FDA letter). The U.S. Court of Appeals for the Seventh Circuit heard Lilly's appeal on September 24, 2026. The latest available entries we reviewed are the October 8 supplemental filings; we found no appeal decision in that record.

This is a separate case from the 11 seller lawsuits, and it isn't counted in them.

Why should you care? It's a fight over which approval and follow-on competition rules would apply. FDA's October 2 letter says an application belongs under the new-drug pathway in section 505—not a biologics license application. Neither classification is marketing approval (FDA letter).

• Biologics follow different rules. FDA says biological products do not qualify for the drug-compounding exemptions in sections 503A and 503B. Separate guidance covers certain mixing, dilution and repackaging of licensed biologics; it is not permission to sell compounded retatrutide (FDA).
• Market protection differs. An eligible original biologic has a 12-year period before approval of a biosimilar—a highly similar follow-on medicine—relying on it can take effect. A drug with a qualifying new active ingredient has a different, five-year exclusivity period. That does not mean every new drug gets five years, or that either rule blocks every competitor or replaces patents (FDA: biologic exclusivity; FDA: drug exclusivity).

So this case could shape future competition and choices. It does not tell us a future price or approval date. We're not taking a side; we're reporting the record.

Is retatrutide part of the Ozempic and Mounjaro lawsuits?

Not in the scope documents we checked. These federal injury cases concern named approved drugs. MDL 3094 concerns stomach and gut injuries; MDL 3163 concerns a specific optic-nerve injury called NAION that can cause vision loss. The court's July 2, 2026 order lists products including Ozempic, Wegovy, Mounjaro and Zepbound—not retatrutide (court order). MDL means related cases grouped for shared pretrial work, not automatically a class action.

For case counts and court orders, see our GLP-1 lawsuits and FDA enforcement tracker.

When can you get real retatrutide?

Retatrutide is not available as an approved prescription medicine. The supervised access pathways we verified are Lilly clinical trials and limited physician-requested expanded access—not a retail peptide seller.

Lilly said on July 23, 2026 that it planned to submit a biologics license application in the first quarter of 2027. FDA's October 2 decision instead directs a new-drug application. The filing plan is not an approval date, and the records do not establish whether the dispute will affect timing (Lilly; FDA).

Expanded access (sometimes called compassionate use) is a narrow process for access to an unapproved drug outside a trial. Lilly's criteria include age 18 or older; BMI of at least 35 despite taking and tolerating the highest available dose of chronic weight-management therapy; at least two serious or life-threatening obesity-related complications being treated; and inability to join a suitable trial. Standard options, including bariatric surgery, must have been discussed. A medical reason not to use retatrutide also rules a patient out.

You cannot apply on your own. Your treating doctor must request it, and acceptance depends on the full assessment, geography and supply (Lilly Medical, reviewed Aug 26, 2026). See retatrutide availability for more on access and trials.

What you can take legally right now

An approved medicine to discuss with your clinician is tirzepatide, sold as Zepbound for weight management and Mounjaro for type 2 diabetes (Zepbound label; Mounjaro label). It's not retatrutide, and a licensed clinician decides if it's right for you. For an honest look at how big the gap is, see retatrutide vs. tirzepatide.

If cost is what pushed you toward reta, check what your insurance covers before you decide the approved path is out of reach.

Start with your own doctor, not an online program, if you're under 18, pregnant or trying to be, have type 1 diabetes, a history of an eating disorder, or a reason a medication's label says not to take it.

On Medicare or Medicaid? Your program's rules come first. Ask your plan about its coverage. For Medicare, start with does Medicare cover Zepbound; Medicaid questions belong with your state program or managed-care plan.

For adults who want help checking insurance for an FDA-approved medicine, Ro offers a free coverage-check service for Ozempic, Wegovy and Zepbound autoinjector pens. A coverage check is not a prescription or a promise your plan will pay.

Ro also lists the Wegovy pill, Foundayo and Zepbound KwikPen, but labels those options cash-pay only (Ro, checked Oct 14, 2026). Ozempic has approved uses in adults with type 2 diabetes, not a weight-loss indication; prescribing it solely for weight loss is off-label (prescribing information, revised May 2026).

Its membership is $39 for the first month, then $149/month on the monthly plan. Ro advertises an annual prepaid rate as low as $74/month: $888 for 12 months at that advertised rate, paid upfront after the introductory month—not $74 billed monthly. We calculated that total from Ro's listed rate; we did not complete checkout. Medication is billed separately. Ro says the membership includes provider support, insurance help and lab testing if needed (pricing and billing terms, checked Oct 14, 2026).

The next step below is the insurance-check signup, not enrollment in the paid membership.

Check your coverage with Ro

A few honest notes so you land in the right place:

• Compounded is a different path. Compounded tirzepatide or semaglutide is not FDA-approved and is not retatrutide. FDA says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs. A lower price or preference alone does not establish that compounding is lawful. Talk to your clinician and read compounded vs. name-brand GLP-1s first (FDA).
• Want other options? We compare the realistic picks in the best retatrutide alternatives.

What we actually verified

On October 14, 2026, we reviewed available docket entries for the 11 seller cases through CourtListener's archive of federal filings. We read the Aesthetic Envy dismissal notice and the available text of the Medrein complaint, and checked the relevant allegations, arguments and requests in the LiveWell complaint and Legendary's motion to dismiss.

We also checked:

• The docket entries for the Lilly v. FDA orders, the Seventh Circuit record and the text of FDA's October 2, 2026 letter
• FDA's current unapproved-GLP-1, compounding and exclusivity guidance
• Lilly's August 12 announcement, July 23 filing plan and expanded-access explanation
• Victoria's official health alert and America's Poison Centers' explanation of its data limits
• Current prescribing information for Zepbound, Mounjaro, Wegovy, Foundayo and Ozempic, limited to the product and approval distinctions used here
• Ro's live offering and pricing pages, its insurance-check destination, and The RX Index's matching-tool page

Reported, not independently confirmed: the two settlements described in news coverage; the two FDA death reports described by CBS; and the quarterly retatrutide exposure figures attributed to America's Poison Centers. We read that coverage, but could not retrieve the underlying death-report copies or obtain the settlement agreements or poison-center data extract. Those items are identified as reported claims, not our legal findings, verified medical outcomes or original dataset.

What we couldn't confirm: which second August case settled; what Lilly's Astra dismissal notice dropped; and the full meaning of later orders that were not available in the archive. We did not review the American Peptides or Cenexa complaints in full. Public court archives can lag behind the official court system, so a very recent filing may not show here yet. The source links let you check for later entries.

What we didn't do: pay for every court filing, test any product, interview anyone, complete Ro's checkout, or test every outcome of the matching tool. We're not lawyers, and nothing here is legal advice.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Our methodology explains how. We don't score lawsuits or defendants.

Frequently asked questions

Should I stock up on retatrutide before sellers disappear?

No. FDA urges consumers not to buy products falsely sold for research while marketed for human use. This page cannot verify a vial's contents or sterility, and stockpiling does not solve that problem. Talk to a clinician about an approved option instead (FDA).

How can Lilly sue over a drug that isn't approved yet?

In the complaints discussed here, Lilly relies on false-advertising or unfair-competition claims, saying the sellers misled buyers and hurt its business, including sales of approved drugs. Legendary Peptides argues that Lilly has not shown an injury it can sue over that was caused by Legendary. We found no ruling deciding that motion in the public record reviewed.

Why do Lilly's complaints quote Reddit posts?

In the LiveWell complaint, Lilly cites posts from Reddit groups such as r/Retatrutide. It uses them to show people buying, dosing and switching from Mounjaro or Zepbound, and to point to reported problems like ER visits and skin reactions. Lilly cites those posts to support its allegations about use and marketing. That does not make the posts authenticated facts or clinical proof that any product is safe or unsafe.

Is Lilly suing people who take retatrutide?

Not in these 11 cases. Every named defendant is a business or a person alleged to be selling as a business. That describes these cases only. It isn't a promise about anyone's legal situation.

Can I get in trouble for buying retatrutide?

None of these lawsuits names a buyer, and the FDA's warnings are aimed at sellers while urging consumers not to buy. Laws can differ by state and situation, and we're not lawyers. If you're worried about your own legal risk, ask one.

Did Lilly win the Aesthetic Envy case?

Not exactly. Lilly itself dismissed the whole case with prejudice on September 11, 2026, which means it cannot refile those same dismissed claims against that defendant. The filing doesn't say why and isn't a court finding about the seller or its products.

Can a doctor prescribe compounded retatrutide?

No. The FDA says retatrutide can't be used in compounding under federal law, and a prescription doesn't make it approved. Lilly's expanded-access program is a separate, supervised process your doctor requests directly from Lilly.

Does a lab report mean an online retatrutide product is legit?

No. A certificate of analysis describes results for the sample tested. It isn't FDA approval or, by itself, proof of your vial's contents and sterility. Not being named in these lawsuits isn't proof of quality either.

Can I join these lawsuits or get a refund through them?

These are cases Lilly brought against sellers, not customer class actions or a published refund program. Questions about your purchase go to the seller or your payment provider; keep receipts and messages. A qualified attorney can assess an injury claim or any legal right to take part in a case.

Can I sue if black-market retatrutide hurt me?

That's a question for a lawyer. The scope documents we checked for MDL 3094 and 3163 do not list retatrutide. Keep the packaging, receipts and medical records so an attorney can assess the facts, possible defendants and deadlines.

Do these lawsuits change when retatrutide will be approved?

The records do not establish an effect on timing. Lilly's July 23 plan was a biologics application in the first quarter of 2027; FDA's October 2 letter instead directs the new-drug pathway. A planned application is not an approval date, and the classification dispute is separate from deciding safety and effectiveness (Lilly; FDA).

Sources

Linked sources checked October 14, 2026. Source publication dates are shown separately. News-reported claims and documents we could not retrieve are identified in the verification section.

• Eli Lilly — Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (Aug 12, 2026)
• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current page checked Oct 14, 2026)
• Court records via CourtListener: Aesthetic Envy and dismissal notice · Astra · Legendary Peptides and motion to dismiss · Striker Pharmacy · Texas Peptides · Lone Star Peptide · American Peptides · Cenexa Labs · LiveWell / Brown and complaint · Medrein / Southlake Mhya and complaint · MedShape
• Lilly v. FDA: S.D. Ind. docket · Seventh Circuit docket · FDA letter, Oct 2, 2026
• CBS News — Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? (Oct 13, 2026)
• Becker's Hospital Review — 2 deaths reported to FDA after people took products claiming to be Eli Lilly's retatrutide (Lilly settlement statement)
• FDA — Compounding questions and answers, reference-biologic exclusivity and drug exclusivity
• Lilly — July 23, 2026 filing-plan statement and retatrutide expanded access (medical explanation reviewed Aug 26, 2026)
• America's Poison Centers — GLP-1 information and data limitations
• U.S. District Court — MDL 3163 order identifying products and related MDL 3094 (July 2, 2026)
• Victoria Department of Health — Toxicity linked to unapproved product labelled retatrutide (alert issued June 19, 2026; rechecked Oct 14, 2026)
• FDA — MedWatch
• Manufacturer prescribing information — Zepbound, Mounjaro, Wegovy, Foundayo and Ozempic
• Ro — Weight loss membership, pricing and insurance-check signup